Business Wire

TX-ATSEC-AB

Share
atsec AB first IEEE 2621 Accredited Medical Device Testing Facility

atsec AB Stockholm, Sweden is thrilled to announce: We are the first IEEE Authorized Testing Facility!

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403252100/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IEEE certificate (Graphic: Business Wire)

We've officially been approved as an IEEE Authorized Testing Facility, making atsec AB Stockholm, Sweden the first company able to provide testing of medical devices according to the IEEE 2621 standard. Additional locations include atsec corporation Austin TX, USA and atsec GmbH Munich, Germany.

The IEEE, or Institute of Electrical and Electronics Engineers, is a globally recognized leader in developing technical standards. Earning their authorization as a testing facility demonstrates our capability to conduct rigorous and reliable security evaluations of medical devices according to the IEEE 2621 standard.

Importantly, the IEEE 2621 standard is recognized by the Food and Drug Administration (FDA), the leading regulatory body for medical devices in the United States. This recognition signifies that the FDA considers the standard to be a valuable tool in ensuring medical device security.

Proven Expertise Through Pilot Projects

"We enthusiastically embraced the opportunity to become a player in this domain when IEEE first contacted atsec in July 2022," said Sal La Pietra, President and founder of atsec.

"We're particularly proud of this achievement because it follows the successful completion of two pilot projects that used the IEEE 2621 standard for medical device testing. These projects allowed us to refine our processes and demonstrate our expertise in applying this standard," added Rasma Mozuraite Araby, Managing Director of atsec AB in Stockholm, Sweden.

Looking Ahead: Medical Device Testing

As an IEEE Authorized Testing Facility with laboratories in Sweden, the U.S., and Germany, atsec is now positioned to offer our clients a suite of testing services that ensure their medical devices meet the industry's security benchmarks. If you're looking for a reliable partner to verify the security of your medical devices, contact us today at info@atsec.com to discuss your specific needs.

Link to IEEE listing:

https://standards.ieee.org/products-programs/icap/programs/medical-devices-cybersecurity/#test-labs

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240403252100/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aptiv and Vecna Robotics to Develop Next Generation Autonomous Mobile Robots18.12.2025 14:00:00 CET | Press release

Collaboration to Deliver Safer, Smarter, and Cost-Effective Automation for Warehouses and Factories Aptiv PLC (NYSE: APTV), a global industrial technology leader, and Vecna Robotics, a pioneer in AI-driven autonomous material handling solutions, today announced a strategic collaboration to co-develop next-generation Autonomous Mobile Robot (AMR) solutions designed to deliver cost-efficient automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218958100/en/ Aptiv’s advanced perception portfolio and machine learning technologies will be integrated into Vecna Robotics’ platform. This partnership combines Aptiv’s industry-leading portfolio, with Vecna Robotics’ advanced autonomy and orchestration platform to provide safer, more efficient, and scalable material handling systems. “Automation is transforming the way goods move through warehouses and factories, with devices that sense, think and act in real time,” said Javed

Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions18.12.2025 14:00:00 CET | Press release

Addressing major unmet needs in mental health with pharmacology rooted in emerging and clinically validated neuropsychiatric biologyLead program ST-905, a potent M1/M4 muscarinic agonist, currently in Phase 1 clinical developmentSecond program ST-901, a novel NMDA antagonist, currently in IND-enabling studies and expected to enter Phase 1 development next yearSeries A co-led by Dexcel Pharma and Third Rock Ventures with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet Syremis Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health, today announced its launch with a $165 million financing. The Series A, co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet will support the advancement of Syremis’ pipeline through clinical proof of concept. Schizophrenia and other psychotic disorder

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye